Claudia Matteucci

Prof. Claudia Matteucci

University of Rome Tor Vergata, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in Experimental Cell Research
Verified
Journal Article
Closed access
ASAnnalucia Serafino
Annalucia Serafino
EBE. Balestrieri
E. Balestrieri
PPP. Pierimarchi
P. Pierimarchi
Claudia MatteucciClaudia Matteucci
Claudia Matteucci
GMG. Moroni
G. Moroni
PSPaola Sinibaldi
Paola Sinibaldi

1 April 2021 in EBioMedicine
Verified
Journal Article
Open access
EBEmanuela Balestrieri
Emanuela Balestrieri
antonella minutoloantonella minutolo
antonella minutolo
VPVita Petrone
Vita Petrone
MFMarialaura Fanelli
Marialaura Fanelli
Marco IannettaMarco Iannetta
Marco Iannetta
Claudia MatteucciClaudia Matteucci
Claudia Matteucci
Despite an impressive effort in clinical research, no standard therapeutic approach for coronavirus disease 2019 (COVID-19) patients has been established, highlighting the need to identify early biomarkers for predicting disease progression and new therapeutic interventions for patient management. The present study aimed to evaluate the involvement of the human endogenous retrovirus -W envelope (HERV-W ENV) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection considering recent findings that HERVs are activated in response to infectious agents and lead to various immunopathological effects. We analysed HERV-W ENV expression in blood cells of COVID-19 patients in correlation with clinical characteristics and have discussed its potential role in the outcome of the disease. We analysed HERV-W ENV expression in blood samples of COVID-19 patients and healthy donors by flow cytometry and quantitative reverse transcriptase PCR analysis, and evaluated its correlation with clinical signs, inflammatory markers, cytokine expression, and disease progression. HERV-W ENV was highly expressed in the leukocytes of COVID-19 patients but not in those of healthy donors. Its expression correlated with the markers of T-cell differentiation and exhaustion and blood cytokine levels. The percentage of HERV-W ENV-positive lymphocytes correlated with inflammatory markers and pneumonia severity in COVID-19 patients. Notably, HERV-W ENV expression reflects the respiratory outcome of patients during hospitalization. Given the known immuno- and neuro-pathogenicity of HERV-W ENV protein, it could promote certain pathogenic features of COVID-19 and therefore serve as a biomarker to predict clinical progression of disease and open to further studies for therapeutic intervention. Information available at the end of the manuscript.

1 December 2018 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
Claudia MatteucciClaudia Matteucci
Claudia Matteucci
EBEmanuela Balestrieri
Emanuela Balestrieri
AAAyele Argaw-Denboba
Ayele Argaw-Denboba
PSPaola Sinibaldi-Vallebona
Paola Sinibaldi-Vallebona

26 January 2017 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AAAyele Argaw-Denboba
Ayele Argaw-Denboba
EBEmanuela Balestrieri
Emanuela Balestrieri
ASAnnalucia Serafino
Annalucia Serafino
CCChiara Cipriani
Chiara Cipriani
IBIlaria Bucci
Ilaria Bucci
Claudia MatteucciClaudia Matteucci
Claudia Matteucci
Melanoma is a heterogeneous tumor in which phenotype-switching and CD133 marker have been associated with metastasis promotion and chemotherapy resistance. CD133 positive (CD133+) subpopulation has also been suggested as putative cancer stem cell (CSC) of melanoma tumor. Human endogenous retrovirus type K (HERV-K) has been described to be aberrantly activated during melanoma progression and implicated in the etiopathogenesis of disease. Earlier, we reported that stress-induced HERV-K activation promotes cell malignant transformation and reduces the immunogenicity of melanoma cells. Herein, we investigated the correlation between HERV-K and the CD133+ melanoma cells during microenvironmental modifications. TVM-A12 cell line, isolated in our laboratory from a primary human melanoma lesion, and other commercial melanoma cell lines (G-361, WM-115, WM-266-4 and A375) were grown and maintained in the standard and stem cell media. RNA interference, Real-time PCR, flow cytometry analysis, self-renewal and migration/invasion assays were performed to characterize cell behavior and HERV-K expression. Melanoma cells, exposed to stem cell media, undergo phenotype-switching and expansion of CD133+ melanoma cells, concomitantly promoted by HERV-K activation. Notably, the sorted CD133+ subpopulation showed stemness features, characterized by higher self-renewal ability, embryonic genes expression, migration and invasion capacities compared to the parental cell line. RNA interference-mediated downregulation experiments showed that HERV-K has a decisive role to expand and maintain the CD133+ melanoma subpopulation during microenvironmental modifications. Similarly, non nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and nevirapine were effective to restrain the activation of HERV-K in melanoma cells, to antagonize CD133+ subpopulation expansion and to induce selective high level apoptosis in CD133+ cells. HERV-K activation promotes melanoma cells phenotype-switching and is strictly required to expand and maintain the CD133+ melanoma cells with stemness features in response to microenvironmental modifications.

1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
EBEmanuela Balestrieri
Emanuela Balestrieri
FPFrancesca Pica
Francesca Pica
Claudia MatteucciClaudia Matteucci
Claudia Matteucci
RZRossella Zenobi
Rossella Zenobi
RSRoberta Sorrentino
Roberta Sorrentino
PSPaola Sinibaldi
Paola Sinibaldi
Human endogenous retroviruses (HERVs) have been implicated in human physiology and in human pathology. A better knowledge of the retroviral transcriptional activity in the general population and during the life span would greatly help the debate on its pathologic potential. The transcriptional activity of four HERV families (H, K, W, and E) was assessed, by qualitative and quantitative PCR, in PBMCs from 261 individuals aged from 1 to 80 years. Our results show that HERV-H, HERV-K, and HERV-W, but not HERV-E, are transcriptionally active in the test population already in the early childhood. In addition, the transcriptional levels of HERV-H, HERV-K, and HERV-W change significantly during the life span, albeit with distinct patterns. Our results, reinforce the hypothesis of a physiological correlation between HERVs activity and the different stages of life in humans. Studies aiming at identifying the factors, which are responsible for these changes during the individual’s life, are still needed. Although the observed phenomena are presumably subjected to great variability, the basal transcriptional activity of each individual, also depending on the different ages of life, must be carefully considered in all the studies involving HERVs as causative agents of disease.

14 November 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EBEmanuela Balestrieri
Emanuela Balestrieri
CACarla Arpino
Carla Arpino
Claudia MatteucciClaudia Matteucci
Claudia Matteucci
RSRoberta Sorrentino
Roberta Sorrentino
FPFrancesca Pica
Francesca Pica
PSPaola Sinibaldi
Paola Sinibaldi
Autistic Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental disorder, resulting from complex interactions among genetic, genomic and environmental factors. Here we have studied the expression of Human Endogenous Retroviruses (HERVs), non-coding DNA elements with potential regulatory functions, and have tested their possible implication in autism. The presence of retroviral mRNAs from four HERV families (E, H, K and W), widely implicated in complex diseases, was evaluated in peripheral blood mononuclear cells (PBMCs) from ASD patients and healthy controls (HCs) by qualitative RT-PCR. We also analyzed the expression of the env sequence from HERV-H, HERV-W and HERV-K families in PBMCs at the time of sampling and after stimulation in culture, in both ASD and HC groups, by quantitative Real-time PCR. Differences between groups were evaluated using statistical methods. The percentage of HERV-H and HERV-W positive samples was higher among ASD patients compared to HCs, while HERV-K was similarly represented and HERV-E virtually absent in both groups. The quantitative evaluation shows that HERV-H and HERV-W are differentially expressed in the two groups, with HERV-H being more abundantly expressed and, conversely, HERV-W, having lower abundance, in PBMCs from ASDs compared to healthy controls. PMBCs from ASDs also showed an increased potential to up-regulate HERV-H expression upon stimulation in culture, unlike HCs. Furthermore we report a negative correlation between expression levels of HERV-H and age among ASD patients and a statistically significant higher expression in ASD patients with Severe score in Communication and Motor Psychoeducational Profile-3. Specific HERV families have a distinctive expression profile in ASD patients compared to HCs. We propose that HERV-H expression be explored in larger samples of individuals with autism spectrum in order to determine its utility as a novel biological trait of this complex disorder.